| Literature DB >> 33233821 |
Kassiani Skouloudaki1, Dimitrios K Papadopoulos1, Toby W Hurd1.
Abstract
During development, the precise control of tissue morphogenesis requires changes in the cell number, size, shape, position, and gene expression, which are driven by both chemical and mechanical cues from the surrounding microenvironment. Such physical and architectural features inform cells about their proliferative and migratory capacity, enabling the formation and maintenance of complex tissue architecture. In polarised epithelia, the apical cell cortex, a thin actomyosin network that lies directly underneath the apical plasma membrane, functions as a platform to facilitate signal transmission between the external environment and downstream signalling pathways. One such signalling pathway culminates in the regulation of YES-associated protein (YAP) and TAZ transcriptional co-activators and their sole Drosophila homolog, Yorkie, to drive proliferation and differentiation. Recent studies have demonstrated that YAP/Yorkie exhibit a distinct function at the apical cell cortex. Here, we review recent efforts to understand the mechanisms that regulate YAP/Yki at the apical cell cortex of epithelial cells and how normal and disturbed YAP-actomyosin networks are involved in eye development and disease.Entities:
Keywords: actomyosin; apical cortex; eye development
Mesh:
Substances:
Year: 2020 PMID: 33233821 PMCID: PMC7699867 DOI: 10.3390/ijms21228804
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Domain architecture and protein size for YES-associated protein (YAP) and Yorkie. The annotated domains include the TBD, which indicates a complete TEAD binding domain, the WW1 and WW2 domains (WW), coiled-coil domains (C-C), and the PDZ binding motif. The critical phosphorylation sites of YAP and Yorkie are indicated below the protein structure (in black).
Figure 2Regulation between actin cytoskeleton and Yap/Yorkie at the apical cell cortex in Drosophila and in mammalian cells. (A) In Drosophila cells, cytoplasmic Yki can interact with Tsr at the apical cortex and thus prevent cortical F-actin from Tsr-mediated severing (left branch of the signalling pathway). In this case, Yki’s concentration in the nucleus decreases and the expression of cell proliferation genes is inhibited, thus preventing epithelial growth. Conversely, upstream regulatory mechanical or molecular stimuli, acting through the apical ECM, allow Yki through Strn-Mlck kinase, or independently, to activate Sqh (myosin light chain), which triggers the translocation of Yki to the nucleus (right branch of the signalling pathway). Thereby, cell-proliferation genes become upregulated and the epithelium grows. (B) In mammalian cells, Cofilin in response to low mechanical stresses limits YAP activity in the nucleus. Alternatively, the interaction of YAP with Trio/Dia at the apical cortex triggers the nuclear translocation of YAP and gene expression. Conversely, the expression of YAP target genes such as ARHGEF17, Bcam, S1pr2, and Nuak2 signals to pMLC, whereas the expression of ARHGAP29 signals to Cofilin, which leads to F-actin severing and growth.
YAP pathway-associated eye disease.
| Gene | YAP effects | Disease | Phenotype | Evidence |
|---|---|---|---|---|
| YAP Arg124* | YAP premature stop | Coloboma | Gap in iris, cornea, or eyelid | [ |
| YAP Glu356* | YAP premature stop | Coloboma | Gap in iris, cornea, or eyelid | [ |
| TEAD1 | Abolished interaction with YAP | Sveinsson’s chorioretinal atrophy | Loss of RPE, choroid, and photoreceptor | [ |
| GNAQ | YAP upregulation | Uveal melanoma | Tumour growth | [ |
| GNA11 | YAP upregulation | Uveal melanoma | Tumour growth | [ |
| NF2 | YAP upregulation | Neurofibromatosis 2 | Subcapsular cataract, disorganised lens | [ |
| Ctgf | YAP increased transcription and protein levels | Retinal degeneration | Muller cell gliosis | [ |
| Cyr61 | YAP increased transcription and protein levels | Retinal degeneration | Muller cell gliosis | [ |
|
| YAP haploinsufficiency | Retinal degeneration | Muller cell dysfunction, cone degeneration | [ |
|
| YAP endothelial deficiency | Pathologic retinal vascularisation | Retinal vasculature defects | [ |